Bristol Myers Squibb (BMS) aims to combat sickle cell disease in Sub-Saharan Africa alongside Texas Children's Global HOPE and Baylor College of Medicine Global Health. BMS also extends its reach into the Alzheimer's market with a new schizophrenia drug and its trend-setting stock prepares to become one of the best cheap buy-ins by 2025. Despite the market dip, BMS continues to invest in novel technologies to battle cancer, cardiovascular disease, and autoimmune disorders. Its recent FDA approval of Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy), a drug designed for adult, solid tumor indications, reinforces BMS’s position in the biotech market. AI-empowered workplace innovation and the usage of quick injections instead of medication infusions are leading the charge in BMS's creative healthcare solutions. A collaborative partnership with UTSA aims to advance pharmaceutical discoveries and development, emphasizing the company's commitment to innovation. Meanwhile, BMS promotes diversity by fostering STEM education and using SOGIIS data collection for improved health equity in clinical trials. The bio-pharmaceutical giant celebrates 10 years of Opdivo with FDA approval for a subcutaneous version, signaling further developments on the horizon.
Bristol-Myers Squibb News Analytics from Tue, 02 Apr 2024 07:00:00 GMT to Sat, 18 Jan 2025 22:01:59 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -4
